Lupus News Today Home | Lupus News Today
WEBParvovirus, mpox, and COVID-19: 3 reasons to heighten precautions. Summer news reports show that COVID-19 is surging again. The World Health Organization has declared the mpox outbreak a global health emergency. And human parvovirus B19, which can cause fifth disease, is spreading across the U.S. Scientists are finding that, in …
Lupus overview - Lupus News Today
WEBFeb 9, 2023 · Lupus is a chronic disorder wherein the immune system attacks the body’s own healthy tissue. Lupus can affect virtually every part of the body, including the skin, kidneys, joints, brain, heart, and lungs, resulting in a range of symptoms. Systemic lupus erythematosus (SLE) — often referred to simply as lupus — is the most common and ...
Phase 3 trials of ianalumab for SLE, lupus nephritis now enrolling
WEBJun 15, 2023 · All three trials are being sponsored by Novartis, the company developing ianalumab. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, recently announced that it will be teaming up with Novartis to help run these trials at sites in North America. “We believe this collaboration between Lupus Therapeutics and Novartis Pharmaceuticals will provide a significant ...
Lupkynis protects kidneys in lupus nephritis for up to 3 years
WEBJul 24, 2023 · The therapy is an oral medication approved in US, UK, and EU. by Margarida Maia July 24, 2023. Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 …
News Archives - Lupus News Today
WEBJoint pain very common in lupus, affects patients’ life quality: Study. The vast majority of people with systemic lupus erythematosus (SLE) experience musculoskeletal symptoms, marked by pain, ache, discomfort, and numbness, often in the joints, primarily the hands, wrists, and knees. That’s according to a study from researchers in Egypt ...
LRA awards scientists $600K for work into new treatments for lupus
WEBby Mary Chapman March 14, 2024. The Lupus Research Alliance (LRA) has announced the latest recipients of its Lupus Mechanisms and Targets Award (LMTA), who will investigate molecular pathways or targets that could lead to new or better treatments for lupus. Each of the seven awarded scientists will receive up to $600,000 in funding over three ...
Lupuzor Shows Strong Safety Results as Lupus Treatment in Phase …
WEBSep 29, 2017 · New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma ‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed the full 12-month study. “With an urgent need for a new treatment ...
FDA Clears Automated Diagnosis Tests for Lupus and ANCA …
WEBJun 1, 2018 · The U.S. Food and Drug Administration (FDA) has approved new automated diagnostic tests for lupus and ANCA-associated vasculitis, a form of blood vessel inflammation, Grifols, which will market these tests, announced. The two use the HELIOS system, developed by AESKU, which is the first and only automated system capable of processing and ...
Lupkinis plus MMF most effective as treatment for lupus nephritis
WEBby Andrea Lobo, PhD January 8, 2024. A combination of Lupkinis (viclosporin) with mycophenolate mofetil (MMF) was the most effective at managing lupus nephritis, according to a systematic review of clinical trial data. The treatment was also associated with the highest risk of infections and serious infections, indicating a lower safety profile ...
MyLupus mobile phone app aims to help patients in care decisions
WEBJan 25, 2024 · Goal of new mobile phone app is educating lupus patients. The patient-focused mobile phone app was developed out of a multicenter, observational study dubbed IDEAL (NCT03735238), sponsored by UAB.The $2.2 million Patient-Centered Outcomes Research Institute-funded study, which is still recruiting participants, involves testing three shared decision-making strategies in at least 500 adults with ...